Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities

Myeloid and lymphoid malignancies associated with FGFR1 abnormalities are characterized by constitutive activated FGFR1 kinase and rapid transformation to acute myeloid leukemia and lymphoblastic lymphoma. Molecular targeted therapies have not been widely used for SCLL. Ponatinib (AP24534), that pot...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Mingqiang, Qin, Haiyan, Ren, Ruizhe, Cowell, John K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2012
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3629706/
https://www.ncbi.nlm.nih.gov/pubmed/22781593
http://dx.doi.org/10.1038/leu.2012.188

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3629706/
https://www.ncbi.nlm.nih.gov/pubmed/22781593
http://dx.doi.org/10.1038/leu.2012.188

Ejemplares similares